RT Journal Article
SR Electronic
T1 Explaining ethnic disparities in COVID-19 mortality: population-based, prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.07.21251079
DO 10.1101/2021.02.07.21251079
A1 Batty, G. David
A1 Gaye, Bamba
A1 Gale, Catharine R
A1 Hamer, Mark
A1 Lassale, Camille
YR 2021
UL http://medrxiv.org/content/early/2021/02/10/2021.02.07.21251079.abstract
AB Ethnic disparities in COVID-19 hospitalizations and mortality have been reported but there is scant understanding of how these inequalities are embodied. The UK Biobank prospective cohort study comprises around half a million people who were aged 40-69 years at study induction between 2006 and 2010 when information on ethnic background and potential explanatory factors was captured. Study members were linked to a national mortality registry. In an analytical sample of 448,664 individuals (248,820 women), 354 deaths were ascribed to COVID-19 between 5th March and the end of follow-up on 17th September 2020. In age- and sex-adjusted analyses, relative to White participants, Black study members experienced around seven times the risk of COVID-19 mortality (odds ratio; 95% confidence interval: 7.25; 4.65, 11.33), while there was a doubling in the Asian group (1.98; 1.02, 3.84). Controlling for baseline comorbidities, socioeconomic circumstances, and lifestyle factors explained 53% of the differential in risk for Asian people (1.37; 0.68, 2.77) and 27% in Black study members (4.28; 2.67, 6.86). The residual risk in ethnic minority groups for COVID-19 deaths may be ascribed to unknown genetic factors or unmeasured phenotypes, most obviously racial discrimination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no direct financial support for the work reported in the manuscript. CL is funded by the Beatriu de Pinos postdoctoral programme of the Government of Catalonia's Secretariat for Universities and Research of the Ministry of Economy and Knowledge (2017-BP-00021); GDB by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for UK Biobank was granted to the principal investigators by the North-West Multi-centre Research Ethics Committee, and the research was carried out in accordance with the Declaration of Helsinki of the World Medical Association; participants gave written consent. The present analyses of existing, anonymised data from the study has been conducted using the UK Biobank Resource under Application number 10279.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from UK Biobank (http://www.ukbiobank.ac.uk/) are available to bona fide researchers upon application.